

COMBINATION THERAPY BASED ON PD-1 SIGNAL INHIBITORS

ABSTRACT

A novel therapeutic strategy for the anti-PD-1 antibody therapy is provided.

A pharmaceutical composition which comprises at least one substance selected from the group consisting of the following (i) to (iii) and is administered before, after or simultaneously with the administration of a PD-1 signal inhibitor:

- (i) ROS generators and substances that regulate downstream signaling pathways thereof,
- (ii) substances exhibiting an uncoupling effect and substances that regulate downstream signaling pathways thereof, and
- (iii) amino acids.

[Figure 1]